How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,200 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors Full Text available with Trip Pro

levels of prostate-specific antigen (PSA), large tumor volume, predominant ductal component, high Gleason score (GS), comedo-necrosis, high tumor stage (pT), lymphovascular invasion, and positive surgical margin. High expressions of phospho-mTOR (p-mTOR) as well as low expressions of PSA, phospho-S6 ribosomal protein (pS6) and PanCK were associated with BCR. On multivariable analysis, GS, pT, and immunohistochemical expressions of PanCK and p-mTOR remained independent prognostic factors for BCR.These (...) Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors Ductal adenocarcinoma (DAC) of the prostate is an uncommon histologic subtype whose prognostic factors and immunoprofile have not been fully defined.To define its prognostic factors and immunoprofile, the clinicopathological features, including biochemical recurrence (BCR), of 61 cases of DAC were analyzed. Immunohistochemistry was performed on tissue microarray constructs to assess

2017 Journal of Pathology and Translational Medicine

142. Yes-Associated Protein Expression Is Correlated to the Differentiation of Prostate Adenocarcinoma Full Text available with Trip Pro

different between normal epithelial cells and prostate adenocarcinoma. However, YAP expression level was significantly higher in carcinomas with a high Gleason grades (8-10) than in carcinomas with a low Gleason grades (6-7) (p < .01). There was no statistical correlation between YAP expression and stage, age, prostate-specific antigen level, and tumor volume. Biochemical recurrence (BCR)-free survival was significantly lower in patients with high YAP expressing cancers (p = .02). However high YAP (...) Yes-Associated Protein Expression Is Correlated to the Differentiation of Prostate Adenocarcinoma Yes-associated protein (YAP) in the Hippo signaling pathway is a growth control pathway that regulates cell proliferation and stem cell functions. Abnormal regulation of YAP was reported in human cancers including liver, lung, breast, skin, colon, and ovarian cancer. However, the function of YAP is not known in prostate adenocarcinoma. The purpose of this study was to investigate the role of YAP

2017 Journal of Pathology and Translational Medicine

143. An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3′-deoxy-3′[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma Full Text available with Trip Pro

low incidence of being incorporated into the DNA (<1%). 18F-FLT-PET could have a role in the evaluation of response to targeted therapy. We present here a pilot study where we investigated cellular metabolism and proliferation in patients with prostate cancer before and after targeted therapy. Seven patients with Stage IV prostate adenocarcinoma, candidates for targeted therapy inhibiting the hepatocyte growth factor/tyrosine-protein kinase Met (HGF/C-MET) pathway, were included in this study (...) . The HGF/C-MET pathway is implicated in prostate cancer progression, and an evaluation of the inhibition of this pathway could be valuable. 18F-FLT was performed at baseline and within four weeks post-therapy. Tumor response was assessed semi-quantitatively and using visual response criteria. The range of SUVmax for 18F-FLT at baseline in the prostate varied from 2.5 to 4.2. This study demonstrated that 18F-FLT with positron emission tomography/computerized tomography (18F-FLT PET/CT) had only limited

2017 Diagnostics

144. Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V

? Volker Vervölgyi ? Siw Waffenschmidt Keywords: abiraterone acetate, prednisone, prednisolone, androgen deprivation therapy, prostatic neoplasms, benefit assessment, NCT01715285, NCT00268476 Extract of dossier assessment A17-64 Version 1.0 Abiraterone acetate (prostate cancer) 13 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 (...) platform trial in advanced or metastatic prostate cancer on the comparison of different systemic drug therapies. The STAMPEDE study includes patients with prostate cancer for whom long-term ADT is intended and whose disease concurs with one of the following 3 groups: 1) newly diagnosed disease with presence of distant metastasis or lymph node metastasis, 2) newly diagnosed disease with high risk locally advanced prostate cancer without distant metastasis or lymph node metastasis, 3) recurrent locally

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

145. Padeliporfin for untreated localised prostate cancer

techniques for prostate cancer are more accur New diagnostic techniques for prostate cancer are more accurate at identifying low- ate at identifying low- risk disease risk disease 3.1 NICE's clinical guideline on prostate cancer considers tumours to be low risk if the following criteria are met: serum prostate-specific antigen (PSA) no more than 10 ng/ml, a Gleason score no more than 6, and a clinical stage of T1 to T2a. (The Gleason Score is a grading system that rates the aggressiveness of the 2 (...) largest areas of prostate cancer cells in a tumour. Each area is scored on how healthy it looks, so healthy tissue scores 1 or 2 and abnormal tissue scores 3). The clinical experts explained that the techniques used to diagnose prostate cancer in the NHS are changing, for example, transrectal ultrasound (TRUS) guided biopsy is being replaced by multiparametric MRI. MRI techniques are more accurate at differentiating low-risk disease that does not need treatment, from disease that is likely to progress

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

146. Dietary palmitate cooperates with Src kinase to promote prostate tumor progression. Full Text available with Trip Pro

Dietary palmitate cooperates with Src kinase to promote prostate tumor progression. Numerous genetic alterations have been identified during prostate cancer progression. The influence of environmental factors, particularly the diet, on the acceleration of tumor progression is largely unknown. Expression levels and/or activity of Src kinase are highly elevated in numerous cancers including advanced stages of prostate cancer. In this study, we demonstrate that high-fat diets (HFDs) promoted (...) pathological transformation mediated by the synergy of Src and androgen receptor in vivo. Additionally, a diet high in saturated fat significantly enhanced proliferation of Src-mediated xenograft tumors in comparison with a diet high in unsaturated fat. The saturated fatty acid palmitate, a major constituent in a HFD, significantly upregulated the biosynthesis of palmitoyl-CoA in cancer cells in vitro and in xenograft tumors in vivo. The exogenous palmitate enhanced Src-dependent mitochondrial β-oxidation

2019 Prostate

147. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®): Health Professional Version

in the blood of myeloma patients in all stages of the disease.[ , ] For this reason, when treatment is indicated, systemic treatment must be considered for all patients with symptomatic plasma cell neoplasms. Patients with MGUS or asymptomatic smoldering myeloma do not require immediate treatment but must be followed carefully for signs of disease progression. The major challenge is to separate the stable asymptomatic group of patients who do not require treatment from patients with progressive (...) plasmacytoma. Of the plasma cell neoplasms, a staging system exists only for multiple myeloma. Multiple Myeloma Multiple myeloma is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal (or myeloma) protein (M protein) in the serum and/or urine, along with various clinical parameters, such as hemoglobin and serum calcium concentrations, the number of lytic bone lesions, and the presence or absence of renal failure. Impaired renal function worsens prognosis regardless

2018 PDQ - NCI's Comprehensive Cancer Database

148. Irreversible electroporation for treating prostate cancer

prostate surgery. 2 2 Indications and current treatments Indications and current treatments 2.1 Prostate cancer is usually diagnosed after a blood test in primary care has shown elevated prostate-specific antigen (PSA) levels. A raised PSA is not diagnostic of prostate cancer and a prostate biopsy is required to confirm the diagnosis and further tests are required to stage the extent of the disease. A NICE guideline describes recommendations for the diagnosis and management of prostate cancer. 2.2 Most (...) prostate cancers are either localised or locally advanced at diagnosis. Localised prostate cancer does not usually cause any symptoms, but some men might have some urinary problems or erectile dysfunction. Current treatments for localised disease include active surveillance, radical prostatectomy, external beam radiotherapy and brachytherapy. Hormone therapy (androgen deprivation or anti-androgens) is usually the primary treatment for metastatic prostate cancer, but is increasingly being used

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

149. Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins are Predictive For Biochemical Recurrence After Radical Prostatectomy. Full Text available with Trip Pro

Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins are Predictive For Biochemical Recurrence After Radical Prostatectomy. Postoperative biochemical recurrence occurs in up to 40% of prostate carcinoma patients treated with radical prostatectomy. Primary tumor grade and cribriform architecture are important parameters for clinical outcome; however, their relevance at positive surgical margins has not been completely elucidated yet. We reviewed 835 (...) radical prostatectomy specimens and recorded pT-stage, surgical margin status, Grade Group, and cribriform architecture of the primary tumor and at positive surgical margins. Clinicopathologic parameters and biochemical recurrence-free survival (BCRFS) were used as endpoints. Positive surgical margins were present in 284 (34%) patients, with a median cumulative length of 5.0 mm. In 46%, the Grade Group at the margin was equal to the primary tumor grade, while being lower in 42% and higher in 12

2019 American Journal of Surgical Pathology

150. A multicentre prospective clinical trial of <sup>68</sup>Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: Oligometastatic rate and distribution, compared to standard imaging. (Abstract)

(55%) were oligometastatic. In the oligometastatic group, PSMA positivity was limited to the pelvis in 65% of patients, involving either the prostate or nodes (American Joint Committee on Cancer stage N1). This study found a positive correlation between PSMA-HBED positivity and PSA levels; no other factors were statistically significant.For patients with biochemical relapse with BS and CT demonstrating either no disease or low-volume disease, there is a high overall prevalence of PSMA PET/CT (...) prostate carcinoma in patients with biochemical relapse to determine the prevalence of oligometastatic disease recurrence and its distribution.This is a prospective, multicenter clinical trial of PSMA-HBED PET/CT imaging in patients with early biochemical relapse of prostate carcinoma (median prostate-specific antigen [PSA], 2.55 ng/mL) after definitive prostatectomy (152 patients) or radiation therapy (86 patients) with either no lesions or oligometastatic disease on abdominopelvic CT and bone scan

2019 Biology and Physics

151. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. (Abstract)

was a retrospective evaluation of 1019 patients with prostate cancer who underwent radical prostatectomy between 2005 and 2013 without neoadjuvant or adjuvant therapy. The data on age, prostate-specific antigen (PSA) level at diagnosis, pathological T stage (pT), presence of Gleason pattern 5 (GP5), presence of IDC-P, and surgical margin status were analyzed to predict PSA recurrence after prostatectomy.The median patient age was 67 (range, 45-80) years and the median initial PSA level was 6.8 (range, 0.4-82) ng (...) The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. Although the presence of intraductal carcinoma of the prostate (IDC-P) influences biochemical failure in radical prostatectomy patients, no data are available regarding the impact of its integration into the classification grade group system. Thus, the aim of this study was to enhance the utility of the grade group system by integrating the presence of IDC-P.This study

2019 Prostate

152. Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer

for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: Yes Keywords provided by Bo Dai, Fudan University: Metastatic Castration-Resistant Prostate Cancer circulating tumor cells Prognosis Liquid biopsy Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Neoplastic Cells, Circulating Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital (...) : NCT03089099 Recruitment Status : Recruiting First Posted : March 24, 2017 Last Update Posted : May 1, 2017 See Sponsor: Fudan University Information provided by (Responsible Party): Bo Dai, Fudan University Study Details Study Description Go to Brief Summary: As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed. Considered a "liquid biopsy," these circulating tumor cells

2017 Clinical Trials

153. Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

medications) must be discontinued or substituted at least 4 weeks prior to study entry. Exclusion Criteria: Any evidence of spinal cord compression (radiological or clinical) Prior pelvic malignancy Prior pelvic radiation Concurrent malignancy aside from superficial skin cancers or superficial bladder tumors Inability to undergo prostatectomy, radiotherapy, or ADT Primary small cell carcinoma of the prostate (prostate adenocarcinoma with neuroendocrine differentiation is allowed) Inflammatory bowel (...) for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: Male Gender Based Eligibility: Yes Gender Eligibility Description: Prostate cancer only affects males. Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Biopsy confirmed diagnosis of prostate adenocarcinoma (primary small cell carcinoma of the prostate is not allowed, however adenocarcinoma with neuroendocrine differentiation is allowed) Age 18 Presence of 1-5 visible metastases

2017 Clinical Trials

154. uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness

is one of the most frequent types of cancer in men. The characteristics of the disease varies significantly among patients where some have an indolent type of cancer, from which they will never experience symptoms while others have highly aggressive malignant disease that requires prompt therapeutic action. Treatment of localized prostate cancer is based on a risk stratification, where patients are either offered therapy with curative intent - surgery or radiotherapy - or in case of low-risk disease (...) uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2017 Clinical Trials

155. Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer

Posted : March 18, 2019 Sponsor: Assistance Publique - Hôpitaux de Paris Information provided by (Responsible Party): Assistance Publique - Hôpitaux de Paris Study Details Study Description Go to Brief Summary: The purpose of this study is to determine if trans-rectal microwave ablation of the index tumor of patients with low-risk prostate cancer is sufficiently precise and safe, using MRI-transrectal ultrasound image registration. Condition or disease Intervention/treatment Phase Low-Risk Prostate (...) Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2017 Clinical Trials

156. Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups. Full Text available with Trip Pro

Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups. To combine circulating tumor cell (CTC) isolation by filtration and immunohistochemistry to investigate the presence of CTCs in low, intermediate, and high-risk prostate cancer (PCa). CTCs isolated from these risk groups stained positive for both cytokeratin and androgen receptors, but negative for CD45.Blood samples from 41 biopsy confirmed patients with PCa at different clinical stages such as low (...) identified by immunohistochemistry in low, intermediate, and high-risk groups of patients with PCa.CTCs may be found in all stages of PCa. These CTCs can be used to determine the level of genomic instability at any stage of PCa; this will, in the future, enable personalized patient management.Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

2017 Urologic oncology

157. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer. (Abstract)

Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer. Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC).PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml (...) and/or metastatic disease, intended for ADT were enrolled in the study. CTCs were analysed for expression of PSA prostate specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) before and three months after ADT and related to progression.At inclusion, 46 out of 53 patients (87%) were CTC-positive with a sensitivity and specificity for distant metastases (M1) of 98% and 75%, respectively. In patients with M1-disease, EGFR-detection in CTC was an independent prognostic marker for progression

2017 Prostate

158. Obesity as a Risk Factor for Unfavorable Disease in Low-risk Prostate Cancer and Its Relationship with Anatomic Location of Tumor. (Abstract)

Obesity as a Risk Factor for Unfavorable Disease in Low-risk Prostate Cancer and Its Relationship with Anatomic Location of Tumor. We investigated the influence of obesity on unfavorable disease in men with low risk prostate cancer eligible for active surveillance and verified the underlying relationship with tumor location.We analyzed the records of 890 patients with biopsy Gleason score 6 who underwent radical prostatectomy for prostate cancer via multicore (12 or more) biopsy at our (...) institution. Unfavorable disease was defined as primary Gleason pattern 4 or greater, or pathological stage T3 or greater. Multivariate logistic regression analysis was performed to identify factors associated with unfavorable disease. The association of unfavorable disease with anatomical location of the index tumor was assessed.Overall 216 (24.3%), 544 (61.1%) and 130 men (14.6%) had a body mass index of less than 23 (normal), 23 to 27.5 (overweight) and 27.5 kg/m2 or greater (obese), respectively

2017 Journal of Urology

159. Tumor Volume on Biopsy in Low-Risk Prostate Cancers Managed on Active Surveillance. (Abstract)

Tumor Volume on Biopsy in Low-Risk Prostate Cancers Managed on Active Surveillance. Contemporary clinical guidelines recommend active surveillance of men with low risk prostate cancer. Low risk disease spans any potential volume of Gleason score 6 cancer without sufficient attention to tumor volume in the past. Therefore, we compared tumor characteristics in men at low risk on active surveillance to men treated with radical prostatectomy.We evaluated an institutional cohort of 1,633 men (...) with very low risk disease (clinical stage T1c, prostate specific antigen density less than 0.15 ng/ml/cm3, 2 or more positive cores and 50% or greater core involvement) and low risk disease (clinical stage T2a or less, prostate specific antigen less than 10 ng/ml and Gleason score 6 or less). Among patients at low risk we calculated the proportion who failed to meet very low risk volume criteria (greater than 2 positive cores or greater than 50% core involvement). Clinical and pathological metrics

2017 Journal of Urology

160. Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. Full Text available with Trip Pro

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. Animal model experiments have suggested a role of the DNA repair protein ERCC1 (Excision Repair Cross-Complementation Group 1) in prostate cancer progression.To better understand the impact of ERCC1 protein expression in human prostate cancer, a preexisting tissue microarray (TMA) containing more than 12,000 prostate cancer specimens was analyzed by immunohistochemistry and data were (...) . These latter data suggest a functional relationship of ERCC1 expression with genomic instability.The results of our study demonstrate that expression of ERCC1 - a potential surrogate for genomic instability - is an independent prognostic marker in prostate cancer with particular importance in low-grade tumors.

2017 BMC Cancer

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>